Stock Watch: After The Pandemic, Different Vaccines To The Rescue
Pfizer’s Third-Quarter Results Included Belated Acceptances And Echoes For GSK
From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.
You may also be interested in...
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.
The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.
A rise in childhood pneumonia in China and The Netherlands raised fears of another pandemic but the variety of identified pathogens gave way to the concept of ‘immunity debt’ resulting from the last pandemic.